OnKure Therapeutics, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $95.2M
- Price
- $2.35
- % Change (Daily % change from the live per-ticker quote feed.)
- -4.47%
- Volume
- 260.7K
About
OnKure, Inc., established in 2011 and based in Boulder, Colorado, operates as a biopharmaceutical company primarily engaged in the creation and advancement of precise therapeutic agents for cancer. A core area of their research centers on developing highly selective inhibitors for histone deacetylases. Their current pipeline features OKI-179, an inhibitor specifically engineered to combat a wide spectrum of malignancies, including both blood-related cancers and solid tumor formations.
Quick stats
Shares outstanding40.5M
Computed float24.9M
Float / shares61.5%
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001637715
AI Summary
AI-generated1/7
minorneutralother
OnKure Therapeutics to Participate in the Morgan Stanley Global Healthcare Conference
OnKure Therapeutics announced that senior management will participate in the Morgan Stanley 24th Annual Global Healthcare Conference taking place in New York from September 14 to 16, 2026.
The OnKure management team will be available for one-on-one meetings with interested investors during the event.
OnKure is a clinical-stage biopharmaceutical company focused on precision medicines for vascular anomalies and cancers, targeting PI3Kα.